TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Calidi Biotherapeutics ( (CLDI) ) has issued an announcement.
Calidi Biotherapeutics reported its third quarter 2025 financial results and operational highlights, showcasing advancements in its RedTail platform and CLD-401 compound. The company presented promising preclinical data at the SITC meeting and established a Scientific Advisory Board to support its development efforts. Additionally, Calidi raised $6.9 million through a public offering, strengthening its financial position. Despite a net loss of $5.2 million for the quarter, the company continues to expand its platform capabilities and explore new therapeutic areas, aiming to enhance its industry positioning in virotherapy and genetic medicine delivery.
The most recent analyst rating on (CLDI) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company based in San Diego, California, focusing on the development of targeted therapies to deliver genetic medicines to distal sites of disease. The company’s proprietary Redtail platform utilizes an engineered enveloped oncolytic virus for systemic delivery and targeting of metastatic sites, aiming to shield the virus from immune clearance and effectively reach tumor sites.
Average Trading Volume: 286,222
Technical Sentiment Signal: Sell
Current Market Cap: $7.4M
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.